A TARGETED treatment for men with a specific type of prostate cancer is among three new medicines which have been approved for use in Scotland.
The Scottish Medicines Consortium (SMC) has published advice accepting the use of a number of new drugs.
One of these is olaparib, which treats prostate cancer with a specific gene mutation and is the first targeted treatment for patients with this condition.
It can be used in end-of-life treatment and can prolong the time until the disease progresses.
READ MORE: Scottish Government campaign in push for people to attend smear tests
Cabotegravir, in combination with rilpivirine, has also been approved for adults living with HIV.
It is a long-acting treatment for HIV which must be injected by a health professional every two months.
The SMC also approved chloroprocaine hydrochloride (Ampres), a spinal anaesthesia for planned day-case surgical procedures under 40 minutes.
SMC chair, Mark MacGregor, said: “The committee is pleased to be able to accept these three medicines for use by NHS Scotland.
“Olaparib is the first targeted treatment for patients with prostate cancer.
“Participants in our Pace (patient and clinician engagement) meeting told us of the heavy symptom burden for those living with this condition and how highly valued this treatment will be.
“For those living with HIV, cabotegravir injection offers another option compared to current treatments that all require tablets to be taken every day.
“The chloroprocaine hydrochloride injection offers an additional option for planned surgical procedures lasting less than 40 minutes.”
READ MORE: Nearly a third of calls to Scotland’s NHS 24 Mental Health Hub abandoned
The charity Prostate Cancer UK said it welcomed the approval of olaparib, which provides the first opportunity for prostate cancer to be treated based on the genetic make-up of the cancer.
Dr Matthew Hobbs, director of research at Prostate Cancer UK, said: “Olaparib represents a revolution in prostate cancer treatment and we’re delighted that men in Scotland will soon be able to benefit from its life-extending effects.
“However, without investment in vital genomic testing services, hundreds of men won’t be able to access the tests they need to find out if they could benefit from this drug.”
He urged the Scottish Government to increase genetic testing to ensure no-one missed out on the benefits of the new drug.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here